Dashboard
Manage Tickers

TPSTTempest Therapeutics, Inc.

Nasdaq tempesttx.com


$ 2.03 $ 0.13 (6.84 %)    

Friday, 21-Jun-2024 15:59:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.42 $ -1.26 (-0.26 %)
DIA $ 391.63 $ -0.44 (-0.11 %)
SPY $ 544.47 $ -2.53 (-0.46 %)
TLT $ 93.96 $ 0.00 (0 %)
GLD $ 214.79 $ -3.37 (-1.54 %)
$ 2.01
$ 1.90
$ 0.00 x 0
$ 0.00 x 0
$ 1.88 - $ 2.11
$ 0.17 - $ 9.77
30,784,277
na
44.69M
$ 1.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-19-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-22-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-29-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 03-11-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-12-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 04-01-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 03-15-2018 12-31-2017 10-K
27 11-02-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 03-02-2017 12-31-2016 10-K
31 11-03-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-26-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-16-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

piper-sandler-reiterates-overweight-on-tempest-therapeutics-maintains-8-price-target
Piper Sandler Reiterates Overweight on Tem...
06/21/2024 17:52:41

Piper Sandler analyst Edward Tenthoff reiterates Tempest Therapeutics (NASDAQ:TPST) with a Overweight and maintains $8 price...

Core News & Articles
Dow Jumps Over 300 Points; Zapp Electric V...
06/20/2024 18:35:07

why-jabil-shares-are-trading-lower-by-8-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Jabil Shares Are Trading Lower By 8%? ...
06/20/2024 17:26:29

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
06/20/2024 16:32:10

gold-rises-1-accenture-shares-surge-after-q3-results
Gold Rises 1%; Accenture Shares Surge Afte...
06/20/2024 16:00:55

hc-wainwright--co-reiterates-buy-on-tempest-therapeutics-maintains-47-price-target
HC Wainwright & Co. Reiterates Buy on Temp...
06/20/2024 15:22:41

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 ...

whats-going-on-with-cancer-focused-tempest-therapeutics-stock-on-thursday
What's Going On With Cancer-Focused Tempes...
06/20/2024 13:43:25

Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows...

tempest-therapeutics-announces-data-from-phase-1b2-study-of-amezalpat-tpst-1120-shows-six-month-improvement-in-median-overall-survival-when-combined-with-atezolizumab-and-bevacizumab-in-first-line-treatment-of-unresectable-or-metastatic-hepatocellular-carcinoma
Tempest Therapeutics Announces Data From P...
06/20/2024 12:53:45

21 months median OS in amezalpat arm vs. 15 in control arm50% (20/40) of patients on amezalpat arm remain in survival follow up...

why-vuzix-shares-are-trading-higher-by-around-15-here-are-20-stocks-moving-premarket
Why Vuzix Shares Are Trading Higher By Aro...
06/20/2024 12:22:52

Core News & Articles
Market-Moving News for June 20th
06/20/2024 12:17:43

HROW: 20% | Harrow shares are trading higher after the company announced the manufacture of the first of three commercial-scale...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
06/20/2024 12:05:58

tempest-therapeutics-shares-are-trading-higher-after-the-company-announced-the-tpst-1120-arm-improved-all-efficacy-endpoints-vs-soc-control-in-a-study
Tempest Therapeutics shares are trading hi...
06/20/2024 11:54:02

tempest-therapeutics-reported-amezalpat-tpst-1120-arm-improves-all-efficacy-endpoints-vs-soc-control-in-study-of-amezalpat-tpst-1120-in-first-line-hepatocellular-carcinoma
Tempest Therapeutics Reported Amezalpat (T...
06/20/2024 09:42:56

https://ir.tempesttx.com/static-files/8ba2d665-884e-47f7-89c2-adbba73378b2

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
06/19/2024 20:30:52

hc-wainwright--co-reiterates-buy-on-tempest-therapeutics-maintains-47-price-target
HC Wainwright & Co. Reiterates Buy on Temp...
05/13/2024 12:04:32

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 ...

hc-wainwright--co-reiterates-buy-on-tempest-therapeutics-maintains-47-price-target
HC Wainwright & Co. Reiterates Buy on Temp...
05/10/2024 18:58:40

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 ...

tempest-therapeutics-q1-2024-gaap-eps-036-beats-037-estimate
Tempest Therapeutics Q1 2024 GAAP EPS $(0....
05/09/2024 22:02:43

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of ...

why-byrna-technologies-shares-are-trading-higher-by-around-7-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Byrna Technologies Shares Are Trading ...
04/05/2024 17:06:12

Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-ex...

tempest-announces-publication-of-data-from-phase-1-trial-of-tpst-1120-in-patients-with-advanced-solid-tumors-in-journal-of-cancer-research-communications
Tempest Announces Publication Of Data From...
04/04/2024 12:10:41

TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and ...

hc-wainwright--co-reiterates-buy-on-tempest-therapeutics-maintains-47-price-target
HC Wainwright & Co. Reiterates Buy on Temp...
03/20/2024 10:39:11

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)